Podcasts about Lung

This week, we present an inspiring episode for anyone interested in the history, present, and future of prostate cancer care. In this Legends in Urology installment of the BackTable Urology Podcast, Dr. Gerald Andriole joins guest host Dr. Niraj Badhiwala to reflect on a career that has left a lasting impact on the field. --- SYNPOSIS Dr. Andriole shares personal stories from his upbringing in Northeastern Pennsylvania and his journey into medicine. He reflects on his expedited education through Penn State and Jefferson Medical College and his path to urology. He discusses his pivotal work in prostate cancer screening, including the influence of major trials like The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, and traces the evolution of surgical and diagnostic techniques. The conversation also touches on current innovations and the future of prostate cancer management, offering valuable advice for the next generation of urologists. --- TIMESTAMPS 00:00 - Introduction01:59 - From Childhood to Medical School06:48 - Discovering Urology16:52 - Pioneering Prostate Cancer Screening24:07 - The PLCO Study: Design and Challenges28:57 - Controversies and Criticisms in Prostate Cancer Screening33:29 - Evolving Practices in Prostate Cancer Management44:19 - Future of Prostate Cancer Treatment

Today's guest is the author of the Fantasy Football Consistency Guide (available on Amazon) and the founder of the Fantasy Football Expo in Canton, OH which will be held August 8th-10th.

Discover all of the podcasts in our network, search for specific episodes, get the Optimal Living Daily workbook, and learn more at: OLDPodcast.com. Episode 3012: Dr. Neal breaks down the role of genetics in cholesterol levels and explains how even those with a family history of heart disease can benefit from targeted lifestyle changes. From diet tweaks to exercise strategies, his practical tips empower listeners to take control of their heart health, no matter their DNA. Quotes to ponder: "HDL actually helps the body clear LDL from the arteries, which is why it's good." "One of the most effective ways to lower blood cholesterol and blood pressure quickly is weight loss." "Fiber is so helpful because it helps bind to cholesterol and helps the body get rid of it." Episode references: Omega-3 Fatty Acids (NIH Office of Dietary Supplements): https://ods.od.nih.gov/factsheets/Omega3FattyAcids-Consumer USDA FoodData Central: https://fdc.nal.usda.gov/ National Heart, Lung, and Blood Institute: https://www.nhlbi.nih.gov Learn more about your ad choices. Visit megaphone.fm/adchoices

Discover all of the podcasts in our network, search for specific episodes, get the Optimal Living Daily workbook, and learn more at: OLDPodcast.com. Episode 3012: Dr. Neal breaks down the role of genetics in cholesterol levels and explains how even those with a family history of heart disease can benefit from targeted lifestyle changes. From diet tweaks to exercise strategies, his practical tips empower listeners to take control of their heart health, no matter their DNA. Quotes to ponder: "HDL actually helps the body clear LDL from the arteries, which is why it's good." "One of the most effective ways to lower blood cholesterol and blood pressure quickly is weight loss." "Fiber is so helpful because it helps bind to cholesterol and helps the body get rid of it." Episode references: Omega-3 Fatty Acids (NIH Office of Dietary Supplements): https://ods.od.nih.gov/factsheets/Omega3FattyAcids-Consumer USDA FoodData Central: https://fdc.nal.usda.gov/ National Heart, Lung, and Blood Institute: https://www.nhlbi.nih.gov Learn more about your ad choices. Visit megaphone.fm/adchoices

BUFFALO, NY - June 11, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 29, 2025, titled “Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib.” A team led by first author Jinah Kim, from the University of Vermont Medical Center, and corresponding author Young Kwang Chae, from the Feinberg School of Medicine, reports a clinical case in which a patient with advanced non-small cell lung cancer (NSCLC) carrying rare EGFR mutations responded remarkably to amivantamab after other treatments had failed. The patient experienced a complete resolution of brain and spinal fluid metastases, suggesting that amivantamab may be a viable option for patients with uncommon genetic profiles and limited therapy options. Lung cancer remains one of the leading causes of cancer-related deaths worldwide. Patients with NSCLC who have rare mutations in the EGFR gene often face limited treatment options and poor outcomes, especially when the disease spreads to the brain or spinal fluid. This case involved a 67-year-old man diagnosed with NSCLC who had two rare EGFR mutations—G719A and A289V. After disease progression on osimertinib and other therapies, the patient began amivantamab monotherapy. Within six weeks, his lung tumor shrank by over 30 percent. By six months, imaging confirmed the disappearance of brain metastases and leptomeningeal disease, a serious condition affecting the membranes of the brain and spinal cord. Blood tests showed no detectable cancer-related mutations, and the patient, previously wheelchair-bound, regained the ability to walk and perform daily activities. This response has been sustained for more than 19 months. “Treatment produced a durable response over 19 months, including a 32.2% reduction in tumor size at six weeks, and complete resolution of brain metastases and LMD by six months.” Amivantamab is a bispecific antibody that targets EGFR and MET, two key drivers of tumor growth. While it is approved in combination regimens for common EGFR mutations, its effectiveness as a single agent in rare mutations or in treating brain metastases remains largely unproven. This case challenges the assumption that large antibody drugs cannot cross the blood-brain barrier and suggests that amivantamab may have potential in managing central nervous system involvement. Further research is needed to clarify how the drug achieves these effects and to explore its broader use in patients with rare EGFR mutations and limited treatment options. This case highlights three key findings: amivantamab may be effective against rare EGFR mutations, can be used as monotherapy, and may overcome the challenges of the blood-brain barrier. Although based on a single patient, the results provide encouraging evidence to support further investigation of amivantamab in treating difficult-to-manage forms of NSCLC. DOI - https://doi.org/10.18632/oncotarget.28730 Correspondence to - Young Kwang Chae - young.chae@northwestern.edu Video short - https://www.youtube.com/watch?v=RJX3rmtH7h8 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, amivantamab, monotherapy, rare EGFR mutation, NSCLC, leptomeningeal disease To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Author: Eric R. Heinz, MD, PhD, George Washington University, Washington, DC Section Editor: Yuriy Bronshteyn

Dr. Nathan Pennell and Dr. Cheryl Czerlanis discuss challenges in lung cancer screening and potential solutions to increase screening rates, including the use of AI to enhance risk prediction and screening processes. Transcript Dr. Nate Pennell: Hello, and welcome to By the Book, a monthly podcast series for ASCO Education that features engaging discussions between editors and authors from the ASCO Educational Book. I'm Dr. Nate Pennell, the co-director of the Cleveland Clinic Lung Cancer Program and vice chair of clinical research for the Taussig Cancer Center. I'm also the editor-in-chief for the ASCO Educational Book.  Lung cancer is one of the leading causes of cancer-related mortality worldwide, and most cases are diagnosed at advanced stages where curative treatment options are limited. On the opposite end, early-stage lung cancers are very curable. If only we could find more patients at that early stage, an approach that has revolutionized survival for other cancer types such as colorectal and breast cancer.  On today's episode, I'm delighted to be joined by Dr. Cheryl Czerlanis, a professor of medicine and thoracic medical oncologist at the University of Wisconsin Carbone Cancer Center, to discuss her article titled, "Broadening the Net: Overcoming Challenges and Embracing Novel Technologies in Lung Cancer Screening." The article was recently published in the ASCO Educational Book and featured in an Education Session at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Cheryl, it's great to have you on the podcast today. Thanks for being here. Dr. Cheryl Czerlanis: Thanks, Nate. It's great to be here with you. Dr. Nate Pennell: So, I'd like to just start by asking you a little bit about the importance of lung cancer screening and what evidence is there that lung cancer screening is beneficial. Dr. Cheryl Czerlanis: Thank you. Lung cancer screening is extremely important because we know that lung cancer survival is closely tied to stage at diagnosis. We have made significant progress in the treatment of lung cancer, especially over the past decade, with the introduction of immunotherapies and targeted therapies based on personalized evaluation of genomic alterations. But the reality is that outside of a lung screening program, most patients with lung cancer present with symptoms related to advanced cancer, where our ability to cure the disease is more limited.  While lung cancer screening has been studied for years, the National Lung Screening Trial, or the NLST, first reported in 2011 a significant reduction in lung cancer deaths through screening. Annual low-dose CT scans were performed in a high-risk population for lung cancer in comparison to chest X-ray. The study population was comprised of asymptomatic persons aged 55 to 74 with a 30-pack-year history of smoking who were either active smokers or had quit within 15 years. The low-dose CT screening was associated with a 20% relative risk reduction in lung cancer-related mortality. A similar magnitude of benefit was also reported in the NELSON trial, which was a large European randomized trial comparing low-dose CT with a control group receiving no screening. Dr. Nate Pennell: So, this led, of course, to approval from CMS (Centers for Medicare and Medicaid Services) for lung cancer screening in the Medicare population, probably about 10 years ago now, I think. And there are now two major trials showing an unequivocal reduction in lung cancer-related mortality and even evidence that it reduces overall mortality with lung cancer screening. But despite this, lung cancer screening rates are very low in the United States. So, first of all, what's going on? Why are we not seeing the kinds of screening rates that we see with mammography and colonoscopy? And what are the barriers to that here? Dr. Cheryl Czerlanis: That's a great question. Thank you, Nate. In the United States, recruitment for lung cancer screening programs has faced numerous challenges, including those related to socioeconomic, cultural, logistical, and even racial disparities. Our current lung cancer screening guidelines are somewhat imprecise and often fail to address differences that we know exist in sex, smoking history, socioeconomic status, and ethnicity. We also see underrepresentation in certain groups, including African Americans and other minorities, and special populations, including individuals with HIV. And even where lung cancer screening is readily available and we have evidence of its efficacy, uptake can be low due to both provider and patient factors. On the provider side, barriers include having insufficient time in a clinic visit for shared decision-making, fear of missed test results, lack of awareness about current guidelines, concerns about cost, potential harms, and evaluating both true and false-positive test results.  And then on the patient side, barriers include concerns about cost, fear of getting a cancer diagnosis, stigma associated with tobacco smoking, and misconceptions about the treatability of lung cancer. Dr. Nate Pennell: I think those last two are really what make lung cancer unique compared to, say, for example, breast cancer, where there really is a public acceptance of the value of mammography and that breast cancer is no one's fault and that it really is embraced as an active way you can take care of yourself by getting your breast cancer screening. Whereas in lung cancer, between the stigma of smoking and the concern that, you know, it's a death sentence, I think we really have some work to be made up, which we'll talk about in a minute about what we can do to help improve this.  Now, that's in the U.S. I think things are probably, I would imagine, even worse when we leave the U.S. and look outside, especially at low- and middle-income countries. Dr. Cheryl Czerlanis: Yes, globally, this issue is even more complex than it is in the United States. Widespread implementation of low-dose CT imaging for lung cancer screening is limited by manpower, infrastructure, and economic constraints. Many low- and middle-income countries even lack sufficient CT machines, trained personnel, and specialized facilities for accurate and timely screenings. Even in urban centers with advanced diagnostic facilities, the high screening and follow-up care costs can limit access. Rural populations face additional barriers, such as geographic inaccessibility of urban centers, transportation costs, language barriers, and mistrust of healthcare systems. In addition, healthcare systems in these regions often prioritize infectious diseases and maternal health, leaving limited room for investments in noncommunicable disease prevention like lung cancer screening. Policymakers often struggle to justify allocating resources to lung cancer screening when immediate healthcare needs remain unmet. Urban-rural disparities exacerbate these challenges, with rural regions frequently lacking the infrastructure and resources to sustain screening programs. Dr. Nate Pennell: Well, it's certainly an intimidating problem to try to reduce these disparities, especially between the U.S. and low- and middle-income countries. So, what are some of the potential solutions, both here in the U.S. and internationally, that we can do to try to increase the rates of lung cancer screening? Dr. Cheryl Czerlanis: The good news is that we can take steps to address these challenges, but a multifaceted approach is needed. Public awareness campaigns focused on the benefits of early detection and dispelling myths about lung cancer screening are essential to improving participation rates. Using risk-prediction models to identify high-risk individuals can increase the efficiency of lung cancer screening programs. Automated follow-up reminders and screening navigators can also ensure timely referrals and reduce delays in diagnosis and treatment. Reducing or subsidizing the cost of low-dose CT scans, especially in low- or middle-income countries, can improve accessibility. Deploying mobile CT scanners can expand access to rural and underserved areas.  On a global scale, integrating lung cancer screening with existing healthcare programs, such as TB or noncommunicable disease initiatives, can enhance resource utilization and program scalability. Implementing lung cancer screening in resource-limited settings requires strategic investment, capacity building, and policy interventions that prioritize equity. Addressing financial constraints, infrastructure gaps, and sociocultural barriers can help overcome existing challenges. By focusing on cost-effective strategies, public awareness, and risk-based eligibility criteria, global efforts can promote equitable access to lung cancer screening and improve outcomes.  Lastly, as part of the medical community, we play an important role in a patient's decision to pursue lung cancer screening. Being up to date with current lung cancer screening recommendations, identifying eligible patients, and encouraging a patient to undergo screening often is the difference-maker. Electronic medical record (EMR) systems and reminders are helpful in this regard, but relationship building and a recommendation from a trusted provider are really essential here. Dr. Nate Pennell: I think that makes a lot of sense. I mean, there are technology improvements. For example, our lung cancer screening program at The Cleveland Clinic, a few years back, we finally started an automated best practice alert in our EMR for patients who met the age and smoking requirements, and it led to a six-fold increase in people referred for screening. But at the same time, there's a difference between just getting this alert and putting in an order for lung cancer screening and actually getting those patients to go and actually do the screening and then follow up on it. And that, of course, requires having that relationship and discussion with the patient so that they trust that you have their best interests. Dr. Cheryl Czerlanis: Exactly. I think that's important. You know, certainly, while technology can aid in bringing patients in, there really is no substitute for trust-building and a personal relationship with a provider. Dr. Nate Pennell: I know that there are probably multiple examples within the U.S. where health systems or programs have put together, I would say, quality improvement projects to try to increase lung cancer screening and working with their community. There's one in particular that you discuss in your paper called the "End Lung Cancer Now" initiative. I wonder if you could take us through that. Dr. Cheryl Czerlanis: Absolutely. "End Lung Cancer Now" is an initiative at the Indiana University Simon Comprehensive Cancer Center that has the vision to end suffering and death from lung cancer in Indiana through education and community empowerment. We discuss this as a paradigm for how community engagement is important in building and scaling a lung cancer screening program.  In 2023, the "End Lung Cancer Now" team decided to focus its efforts on scaling and transforming lung cancer screening rates in Indiana. They developed a task force with 26 experts in various fields, including radiology, pulmonary medicine, thoracic surgery, public health, and advocacy groups. The result of this work is an 85-page blueprint with key recommendations that any system and community can use to scale lung cancer screening efforts. After building strong infrastructure for lung cancer screening at Indiana University, they sought to understand what the priorities, resources, and challenges in their communities were. To do this, they forged strong partnerships with both local and national organizations, including the American Lung Association, American Cancer Society, and others. In the first year, they actually tripled the number of screening low-dose CTs performed in their academic center and saw a 40% increase system-wide. One thing that I think is the most striking is that through their community outreach, they learned that most people prefer to get medical care close to home within their own communities. Establishing a way to support the local infrastructure to provide care became far more important than recruiting patients to their larger system.  In exciting news, "End Lung Cancer Now" has partnered with the IU Simon Comprehensive Cancer Center and IU Health to launch Indiana's first and only mobile lung screening program in March of 2025. This mobile program travels around the state to counties where the highest incidence of lung cancer exists and there is limited access to screening. The mobile unit parks at trusted sites within communities and works in partnership, not competition, with local health clinics and facilities to screen high-risk populations. Dr. Nate Pennell: I think that sounds like a great idea. Screening is such an important thing that it doesn't necessarily have to be owned by any one particular health system for their patients. I think. And I love the idea of bringing the screening to patients where they are. I can speak to working in a regional healthcare system with a main campus in the downtown that patients absolutely hate having to come here from even 30 or 40 minutes away, and they'd much rather get their care locally. So that makes perfect sense.  So, under the current guidelines, there are certainly things that we can do to try to improve capturing the people that meet those. But are those guidelines actually capturing enough patients with lung cancer to make a difference? There certainly are proposals within patient advocacy communities and even other countries where there's a large percentage of non-smokers who perhaps get lung cancer. Can we expand beyond just older, current and heavy smokers to identify at-risk populations who could benefit from screening? Dr. Cheryl Czerlanis: Yes, I think we can, and it's certainly an active area of research interest. We know that tobacco is the leading cause of lung cancer worldwide. However, other risk factors include secondhand smoke, family history, exposure to environmental carcinogens, and pulmonary diseases like COPD and interstitial lung disease. Despite these known associations, the benefit of lung cancer screening is less well elucidated in never-smokers and those at risk of developing lung cancer because of family history or other risk factors. We know that the eligibility criteria associated with our current screening guidelines focus on age and smoking history and may miss more than 50% of lung cancers. Globally, 10% to 25% of lung cancer cases occur in never-smokers. And in certain parts of the world, like you mentioned, Nate, such as East Asia, many lung cancers are diagnosed in never-smokers, especially in women. Risk-prediction models use specific risk factors for lung cancer to enhance individual selection for screening, although they have historically focused on current or former smokers.  We know that individuals with family members affected by lung cancer have an increased risk of developing the disease. To this end, several large-scale, single-arm prospective studies in Asia have evaluated broadening screening criteria to never-smokers, with or without additional risk factors. One such study, the Taiwan Lung Cancer Screening in Never-Smoker Trial, was a multicenter prospective cohort study at 17 medical centers in Taiwan. The primary outcome of the TALENT trial was lung cancer detection rate. Eligible patients aged 55 to 75 had either never smoked or had a light and remote smoking history. In addition, inclusion required one or more of the following risk factors: family history of lung cancer, passive smoke exposure, history of TB or COPD, a high cooking index, which is a metric that quantifies exposure to cooking fumes, or a history of cooking without ventilation. Participants underwent low-dose CT screening at baseline, then annually for 2 years, and then every 2 years for up to 6 years. The lung cancer detection rate was 2.6%, which was higher than that reported in the NLST and NELSON trials, and most were stage 0 or I cancers. Subsequently, this led to the Taiwan Early Detection Program for Lung Cancer, a national screening program that was launched in 2022, targeting 2 screening populations: individuals with a heavy history of smoking and individuals with a family history of lung cancer.  We really need randomized controlled trials to determine the true rates of overdiagnosis or finding cancers that would not lead to morbidity or mortality in persons who are diagnosed, and to establish whether the high lung detection rates are associated with a decrease in lung cancer-related mortality in these populations. However, the implementation of randomized controlled low-dose CT screening trials in never-smokers has been limited by the need for large sample sizes, lengthy follow-up, and cost.  In another group potentially at higher risk for developing lung cancer, the role of lung cancer screening in individuals who harbor germline pathogenic variants associated with lung cancer also needs to be explored further. Dr. Nate Pennell: We had this discussion when the first criteria came out because there have always been risk-based calculators for lung cancer that certainly incorporate smoking but other factors as well and have discussion about whether we should be screening people based on their risk and not just based on discrete criteria such as smoking. But of course, the insurance coverage for screening, you have to fit the actual criteria, which is very constrained by age and smoking history. Do you think in the U.S. there's hope for broadening our screening beyond NLST and NELSON criteria? Dr. Cheryl Czerlanis: I do think at some point there is hope for broadening the criteria beyond smoking history and age, beyond the criteria that we have typically used and that is covered by insurance. I do think it will take some work to perhaps make the prediction models more precise or to really understand who can benefit. We certainly know that there are many patients who develop lung cancer without a history of smoking or without family history, and it would be great if we could diagnose more patients with lung cancer at an earlier stage. I think this will really count on there being some work towards trying to figure out what would be the best population for screening, what risk factors to look for, perhaps using some new technologies that may help us to predict who is at risk for developing lung cancer, and trying to increase the group that we study to try and find these early-stage lung cancers that can be cured. Dr. Nate Pennell: Part of the reason we, of course, try to enrich our population is screening works better when you have a higher pretest probability of actually having cancer. And part of that also is that our technology is not that great. You know, even in high-risk patients who have CT scans that are positive for a screen, we know that the vast majority of those patients with lung nodules actually don't have lung cancer. And so you have to follow them, you have to use various models to see, you know, what the risk, even in the setting of a positive screen, is of having lung cancer.  So, why don't we talk about some newer tools that we might use to help improve lung cancer screening? And one of the things that everyone is super excited about, of course, is artificial intelligence. Are there AI technologies that are helping out in early detection in lung cancer screening? Dr. Cheryl Czerlanis: Yes, that's a great question. We know that predicting who's at risk for lung cancer is challenging for the reasons that we talked about, knowing that there are many risk factors beyond smoking and age that are hard to quantify. Artificial intelligence is a tool that can help refine screening criteria and really expand screening access. Machine learning is a form of AI technology that is adept at recognizing patterns in large datasets and then applying the learning to new datasets. Several machine learning models have been developed for risk stratification and early detection of lung cancer on imaging, both with and without blood-based biomarkers. This type of technology is very promising and can serve as a tool that helps to select individuals for screening by predicting who is likely to develop lung cancer in the future.  A group at Massachusetts General Hospital, represented in our group for this paper by my co-authors, Drs. Fintelmann and Chang, developed Sybil, which is an open-access 3D convolutional neural network that predicts an individual's future risk of lung cancer based on the analysis of a single low-dose CT without the need for human annotation or other clinical inputs. Sybil and other machine learning models have tremendous potential for precision lung cancer screening, even, and perhaps especially, in settings where expert image interpretation is unavailable. They could support risk-adapted screening schedules, such as varying the frequency and interval of low-dose CT scans according to individual risk and potentially expand lung cancer screening eligibility beyond age and smoking history. Their group predicts that AI tools like Sybil will play a major role in decoding the complex landscape of lung cancer risk factors, enabling us to extend life-saving lung cancer screening to all who are at risk. Dr. Nate Pennell: I think that that would certainly be welcome. And as AI is working its way into pretty much every aspect of life, including medical care, I think it's certainly promising that it can improve on our existing technology.  We don't have to spend a lot of time on this because I know it's a little out of scope for what you covered in your paper, but I'm sure our listeners are curious about your thoughts on the use of other types of testing beyond CT screening for detecting lung cancer. I know that there are a number of investigational and even commercially available blood tests, for example, for detection of lung cancer, or even the so-called multi-cancer detection blood tests that are now being offered, although not necessarily being covered by insurance, for multiple types of cancer, but lung cancer being a common cancer is included in that. So, what do you think? Dr. Cheryl Czerlanis: Yes, like you mentioned, there are novel bioassays such as blood-based biomarker testing that evaluate for DNA, RNA, and circulating tumor cells that are both promising and under active investigation for lung cancer and multi-cancer detection. We know that such biomarker assays may be useful in both identifying lung cancers but also in identifying patients with a high-risk result who should undergo lung cancer screening by conventional methods. Dr. Nate Pennell: Anything that will improve on our rate of screening, I think, will be welcome. I think probably in the future, it will be some combination of better risk prediction and better interpretation of screening results, whether those be imaging or some combination of imaging and biomarkers, breath-based, blood-based. There's so much going on that it is pretty exciting, but we're still going to have to overcome the stigma and lack of public support for lung cancer screening if we're going to move the needle. Dr. Cheryl Czerlanis: Yes, I think moving the needle is so important because we know lung cancer is still a very morbid disease, and our ability to cure patients is not where we would like it to be. But I do believe there's hope. There are a lot of motivated individuals and groups who are passionate about lung cancer screening, like myself and my co-authors, and we're just happy to be able to share some ways that we can overcome the challenges and really try and make an impact in the lives of our patients. Dr. Nate Pennell: Well, thank you, Dr. Czerlanis, for joining me on the By the Book Podcast today and for all of your work to advance care for patients with lung cancer. Dr. Cheryl Czerlanis: Thank you, Dr. Pennell. It's such a pleasure to be with you today. Thank you. Dr. Nate Pennell: And thank you to our listeners for joining us today. You'll find a link to Dr. Czerlanis' article in the transcript of this episode.  Please join us again next month for By the Book's next episode and more insightful views on topics you'll be hearing at the education sessions from ASCO meetings throughout the year, and our deep dives on approaches that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Nathan Pennell    @n8pennell   @n8pennell.bsky.social Dr. Cheryl Czerlanis Follow ASCO on social media:     @ASCO on X (formerly Twitter)     ASCO on Bluesky    ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Nate Pennell:        Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron       Research Funding (Institution): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi    Dr. Cheryl Czerlanis: Research Funding (Institution): LungLife AI, AstraZeneca, Summit Therapeutics

This episode is with a good friend and collaborator, Dr. Marco Meucci of COSMED. Marco was formally an Associate Professor in the Public Health and Exercise Science Department at Appalachian State University, where he also served as the Director of their wellness and human performance lab. He now is the Academics Manager for COSMED, an Italian company that “designs, manufactures, and sells worldwide diagnostic medical devices to assess Lung function, Metabolic, and Body Composition.” Marco shares his story and progression as an athlete, student, professor, and leader in academia. We discuss how he made decisions leading to where he is today and how he uses the sparks to create forks in life, then takes the most exciting one. We believe you are going to love the energy and insight this enthusiastic Italian brings to the show. Enjoy!

This episode outlines the journey of congenital lung malformations from diagnosis to treatment. Join Dr. Kathleen Dominguez as she discusses the types of lung malformations and the treatment options available during pregnancy and after birth, ensuring parents know what to expect.

Join me live every Monday at 8 PM EST, and let's crush those NCLEX goals together. Be part of a supportive community that's dedicated to your success. Sign up today at ReMarNurse.com/RNU and get your free workbook to keep you on track: https://bit.ly/RNU2025. This is your moment—see you in class!   Join Prof. Regina Callion, MSN RN the #1 instructor on the planet as she provides an insightful overview of lung sounds—what they mean, how to assess them, and their importance in nursing practice. Learn nursing priorities and key considerations to enhance patient care. Perfect for nursing students and professionals aiming to deepen their understanding of respiratory assessment! Don't forget to like, comment, and subscribe for more informative content on nursing and healthcare topics.   Download the ReMar V2 App: ►For iOS: https://apps.apple.com/us/app/remar-v2/id6468063785 ►For Android: https://play.google.com/store/apps/details... ► Find JOBS: http://ReMarNurse.com/jobs ► NCLEX for Africa - http://ReMarNurse.com/KENYA ► Get NCLEX V2: http://www.ReMarNurse.com ►NCLEX V2 Free Trial - http://ReMarNurse.com/free ► FOLLOW ReMar on Instagram: https://www.instagram.com/ReMarNurse/ ► LIKE ReMar on Facebook: https://www.facebook.com/ReMarReview/ ► Subscribe Now on YouTube - http://bit.ly/ReMar-Subscription  

Nghe trọn nội dung sách nói Bắt Đầu Bằng Để Lại trên ứng dụng Voiz FM: https://voiz.vn/play/6668/Một tập tạp văn nhiều cung bậc hỉ nộ ái ố về lòng người và thói đời từ Chuyện đời, Chuyện sách tới Chuyện người. Tác giả viết mà tựa như đang khề khà cùng bạn đọc đối ẩm bằng cái duyên chữ khó phai.Những vấn đề thời sự ùa vào khiến trang viết nhộn hẳn lên với hàng loạt “Ca dao mới thời cách lý”, “Test… đi vào thơ”. Để cuối cùng dẫn tới cú “làm bàn” cực hóm, cực chuẩn: Trong khi công lý đòi hỏi phải được thực thi, công luận đang dùng sức mạnh ngôn từ để bày tỏ thái độ không dung thứ: Dân ta gọi chúng là bọn Việt ác (theo cách cấu tạo từ hệt như Việt gian), là lũ “ăn” kit (theo cách chơi chữ bằng đồng âm)!Đang hóm hỉnh đó rồi tác giả chợt làm người ta đắng đót khi những cái tên đất và người của mấy trăm năm, của máu thịt như Cái Tràm, Láng Dài, Xóm Lung, Đìa Chuối hay Nụ, Thắm, Tươi, Ngà bị chối bỏ dễ dàng. Có phải vì lòng ta cạn, không đủ yêu, không đủ thương, không đủ hãnh diện về cái tiếng quê mình?Và cả những trăn trở day dứt rằng: Thà rằng, xin cứ kỳ vọng con mình phải trở nên giàu có, cao sang, quyền quý, nổi tiếng, thành đạt, ông này bà nọ, xuống ngựa lên xe… nhưng đừng gọi là “công dân đẳng cấp”. Vì thế hẳn có loại “công dân thứ cấp”, và cả loại “phó thường dân” chưa xếp hạng. Thật là, chỉ dùng có mấy chữ mà làm đau lòng không biết bao nhiêu người.Tại ứng dụng sách nói Voiz FM, sách nói Bắt Đầu Bằng Để Lại được đầu tư chất lượng âm thanh và thu âm chuyên nghiệp, tốt nhất để mang lại trải nghiệm nghe tuyệt vời cho bạn. ---Về Voiz FM: Voiz FM là ứng dụng sách nói podcast ra mắt thị trường công nghệ từ năm 2019. Với gần 2000 tựa sách độc quyền, Voiz FM hiện đang là nền tảng sách nói podcast bản quyền hàng đầu Việt Nam. Bạn có thể trải nghiệm miễn phí đa dạng nội dung tại Voiz FM từ sách nói, podcast đến truyện nói, sách tóm tắt và nội dung dành cho thiếu nhi. ---Voiz FM website: https://voiz.vn/ Theo dõi Facebook Voiz FM: https://www.facebook.com/VoizFM Tham khảo thêm các bài viết review, tổng hợp, gợi ý sách để lựa chọn sách nói dễ dàng hơn tại trang Blog Voiz FM: http://blog.voiz.vn/ ---Cảm ơn bạn đã ủng hộ Voiz FM. Nếu bạn yêu thích sách nói Bắt Đầu Bằng Để Lại và các nội dung sách nói podcast khác, hãy đăng ký kênh để nhận thông báo về những nội dung mới nhất của Voiz FM channel nhé. Ngoài ra, bạn có thể nghe BẢN FULL ĐỘC QUYỀN hàng chục ngàn nội dung Chất lượng cao khác tại ứng dụng Voiz FM.Tải ứng dụng Voiz FM: voiz.vn/download#voizfm #sáchnói #podcast #sáchnóiBắtĐầuBằngĐểLại #DươngThànhTruyền

Episode Summary McKenzie and Io chin wag about Conclave, the two popes and Catholicism and make a case for why Conclave should be ushered in gay film canon (a buncha messy flamboyant divas in iconic outfits backstab each other and treat women weirdly to see which of their boys gets to be the man?) What's better than this? Guys being dudes. Host Info Io can be found on Twitter @Bum_lung or on Instagram @Bum.Lung or you can find shirts and patches that they make on Etsy at https://www.etsy.com/shop/BumLung Publisher This show is published by Strangers in A Tangled Wilderness. We can be found at www.tangledwilderness.org, or on Twitter @TangledWild and Instagram @Tangled_Wilderness. You can support the show on Patreon at www.patreon.com/strangersinatangledwilderness. Our logo is by Robin Savage. And our theme music is by a lovely mountain goblin.

This episode of Side Projects features a duo of duos: Charming Disaster and Lung. So naturally, we started the show by discussing musical duos. Somehow we wrapped everything up by talking about sad kazoo music. I don't know how we got there. It really doesn't matter because this episode goes completely off the rails very quickly. But that's why it's so much fun. We do talk about drum shoes, setting microphones on fire, and new albums for both Charming Disaster and Lung. Charming Disaster's is out and about and Lung's will be released shortly. Give them both follows @charmingdisasterband and @lungtheband. Follow us @PerformanceAnx. Buy merch at performanceanx.threadless.com or just throw money at us at ko-fi.com/performanceanxiety. Now brace yourselves for whatever this episode is; because I'm not sure. Learn more about your ad choices. Visit megaphone.fm/adchoices

On this episode I sit down with Gunk Lung and New Neighbors during their recent tour through the midwest. We spend some time talking about their show at Memory lanes before catching up on some origin stories. Be sure to follow Gunk Lung and New Neighbors and check out "The Burner Split"!!!This episode features the songs "A Balance"(New Neighbors) and "Car On Fire"(Gunk Lung" from The Burner Split.You can find Gunk Lung at the following links:Instagram: https://www.instagram.com/gunklungmusicBandcamp: https://gunklungmusic.bandcamp.comYoutube: https://www.youtube.com/@gunklungmusic/Everywhere else: https://linktr.ee/gunklungmusicYou can find Birthday Dad at the following links:Instagram: https://www.instagram.com/newneighborsia/Bandcamp: https://newneighborsia.bandcamp.com/Youtube: https://www.youtube.com/@NewNeighborsIA/_______________________________________You can find Beers With Bands here:Facebook: https://www.facebook.com/BeersWithBands2Twitter: https://twitter.com/BeersWBandsPodInstagram: https://www.instagram.com/beerswithbandspod/Bandcamp: https://beerswithbands.bandcamp.comEverywhere else: https://linktr.ee/BeersWithBandsLogo and Banner design by Kaylyn ChileenInstagram: https://www.instagram.com/madam.fortress.mommy/Website: https://kaylynchileen.artBeers With Bands intro by Thomas Allen of Say Days Ago and Last AutumnSay Days Ago: https://www.instagram.com/saydaysagoband/Last Autumn: https://www.instagram.com/lastautumnband/

VOV1 - Là nơi đa dạng sinh học với nhiều hệ động, thực vật phong phú đặc trưng của vùng sông nước miền Tây nên từ lâu Khu bảo tồn thiên nhiên Lung Ngọc Hoàng ở huyện Phụng Hiệp, tỉnh Hậu Giang được mệnh danh là “lá phổi xanh” của vùng ĐBSCL.

On this week’s podcast, Barry Dolan shares his favourite new music tracks from the louder end of the amorphous blob of new musical genres we cover. Artist “Track” [Album] [edit] radio podcast 774 – Right Click and Save As to Download The post Podcast 774 | Featuring Turbo Panda, Lung, and Rocket appeared first on .

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Adriana Herrera, CEO at Pierre Fabre Pharmaceuticals (USA). Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adriana, covering: Why Big Pharma is such a great training ground for future pharma leaders, and how a period living and working in Mexico defined her leadership style The reality of being purchased by a big pharma like Gilead, and retaining independence as the acquired company, Kite Pharma The opening of a market opportunity that led Adriana to her first CEO role, and how the role is pushing her outside of her comfort zone Why she is optimistic about the future of manufacturing and commercialising cell therapies - innovation will find a way, but it takes time How the current geopolitical environment is adding more risk and uncertainty to an industry plagued with risk... and how that may impact investments and supply chains Adriana leads the expansion of Pierre Fabre's US presence in precision oncology, cell therapy and rare diseases with an immediate focus on the commercialization of a groundbreaking allogenic cell therapy. Most recently, Adriana served as U.S. General Manager at Kite Pharma where she successfully commercialized the autologous CART-cell therapy portfolio and led the US commercial functions. Prior to that, her experience included a tenure at Eisai as Senior Vice President and commercial head for U.S. Oncology and high-impact leadership roles at Novartis Oncology including Vice President and Global Diseases Lead for Lung and Genitourinary cancers. Adriana commenced her career at Bristol Myers-Squibb. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Harrison's rise—from Hong Kong to Canada, Waterloo to McKinsey, and now Group Chief Strategy Officer at e&—is a story of reinvention, vision, and driving global transformation. His insights on AI, telecom, and strategic foresight are reshaping the industry.00:09- About Harrison LungHarrison Lung is the Group Chief Strategy Officer of e&.He was appointed in 2023 and oversees corporate strategy and planning, mergers and acquisitions (M&A), venture capital, Group transformation, ESG and sustainability.

Wet or dry. Air in or out. Reactive or obstructive. The possibilities may seem endless when treating the pediatric patient with undifferentiated respiratory distress. It is confounded by the fact that pediatrics are outside the comfort zone of many novice critical care transport providers. In this podcast episode, neonatal/pediatric specialist Nate Brown eases your worries with concise and effective means of diagnostics and intervention. Primarily, we cover croup, bronchiolitis, and asthma disease processes. Get CE hours for our podcast episodes HERE! -------------------------------------------- Twitter @heavyhelmet Facebook @heavyliesthehelmet Instagram @heavyliesthehelmet Website heavyliesthehelmet.com Email contact@heavyliesthehelmet.com Disclaimer: Heavy Lies the Helmet's content is for educational purposes only and does not constitute medical advice. Always follow local guidelines and consult qualified professionals before applying any information. The hosts and guests are not responsible for errors, omissions, or outcomes. Views expressed are their own and do not reflect their employers or affiliates. --------------------------------------------  Crystals VIP by From The Dust | https://soundcloud.com/ftdmusic Music promoted by https://www.free-stock-music.com

Brooklyn-based goth-folk duo Charming Disaster's upcoming album The Double—their seventh full-length release—explores the world that exists behind the one we know, featuring songs inspired by nature, mortality, magic, ritual, and literary genres ranging from science fiction to Victorian horror. The new album was co-produced by band members Ellia Bisker and Jeff Morris with longtime collaborator, recording engineer Don Godwin. All but one of the ten tracks were recorded at Tonal Park in Takoma Park, MD, with one song recorded by circus music composer Peter Bufano in Boston, MA. The Double will be released on CD, as a 12-inch colored vinyl LP, and on all digital platforms on May 16, 2025. The vinyl will be released in a 2-disc package that also includes Charming Disaster's 2024 compilation Time Ghost, a collection of singles released over the last decade.   The Double invites listeners to step across the border of an alternate reality, where spells are cast, time travel is possible, plants are taking over civilization, and vampires lurk in the shadows. Adventures in the darkness lie beyond the threshold.   The album's ten songs include “Black Locust,” a lullaby about mortality; “New Moon,” a magical nature ritual; “Trick of the Light,” a reimagining of Bram Stoker's Dracula; “Time Machine,” in which Charming Disaster change the past and start over again; “Scavengers,” a walk in the woods with vultures and bones; “Beautiful Night,” a defiant response to struggles with depression; “Vitriol,” a tribute to artist Thomas Little, who turns guns into ink; “Haunted Lighthouse,” a swashbuckling sea voyage; “Gang of Two,” a true crime adventure; and “Green Things,” a love letter to what grows between the cracks (and its inevitable takeover).   The album features an array of talented collaborators. Co-producer Don Godwin, who has worked on Charming Disaster's entire discography, contributed bass, drums, and horns as well as engineering and mixing. “Haunted Lighthouse” features Broadway percussionist Mike Dobson along with circus composer Peter Bufano, who played piano and accordion and engineered the track at Cirkestra World Headquarters in Boston, MA (with additional tracking at Tonal Park). “Scavengers” features cello recorded by Kate Wakefield of the duo Lung, who also created the string arrangement for “Beautiful Night.” Stefan Zeniuk of Gato Logo contributed saxophone to “Green Things.”   In conjunction with The Double, Charming Disaster is releasing the second edition of their “oracle deck” (similar to a Tarot deck). The Charming Disaster Oracle Deck contains 72 cards (including 12 new cards for the second edition), each representing one of the songs from Charming Disaster's discography. The cards feature illustrations commissioned from more than thirty different artists. The deck can be used as a divination tool, or as a visual accompaniment to Charming Disaster's music. The duo themselves use these cards in their live performances to determine the set through the element of chance.   Charming Disaster was formed by Bisker and Morris in 2012, inspired by the gothic humor of Edward Gorey and Tim Burton, the murder ballads of the American Folk tradition, and the dramatic flair of the cabaret. Together the duo write songs that tell stories about myth, magic, and mortality, using two voices to explore dark narratives and characters with a playfully macabre sensibility.   On their critically acclaimed albums Love, Crime & Other Trouble (2015), Cautionary Tales (2017), and SPELLS + RITUALS (2019), Charming Disaster explored death, crime, folklore, and the occult. On Our Lady of Radium (2022), they turned their attention to science and explored the life and discoveries of pioneering scientist Marie Curie. On Super Natural History (2023), they united the natural world and the metaphysical realm in a musical cabinet of curiosities.   The duo put out two releases in 2024: Time Ghost, an album-length collection of songs released as singles between 2013 and 2024; and Dance Me to the End of Bela Lugosi's Lovesong, an EP of covers paying tribute to a few of the band's influences: Leonard Cohen's “Dance Me to the End of Love,” “Bela Lugosi's Dead” by Bauhaus, and The Cure's “Lovesong.”   In Charming Disaster's live shows, the duo combine vocal harmonies and clever lyrics with ukulele, guitar, and foot percussion, with a cabaret-influenced performance style that straddles the line between concert and theatre and has been described as “haunted vaudeville” (Splice Magazine). Charming Disaster's music has been featured on the spooky hit podcast Welcome to Night Vale. They have opened for legendary cello-rock ensemble Rasputina, Goth icon Voltaire, and Amanda Palmer's punk cabaret duo The Dresden Dolls. Their concerts have captivated audiences across the United States and in Europe. They have appeared alongside storytellers, comedians, fire eaters, puppets, burlesque artists, poets, and circus performers. Recent appearances have included Joe's Pub in NYC, Atlanta's massive pop culture convention Dragon Con, Brooklyn's historic Green-Wood Cemetery, the Rochester Fringe Festival, Philadelphia's Science History Institute, the Edgar Allan Poe Museum in Richmond, VA, Cleveland's WizbangCircus Theatre, and the Coney Island Sideshow stage, as well as sundry bars, art galleries, theatres, bookstores, libraries, train cars, mausoleums, and museums.   LINKS: Website: www.charmingdisaster.com Facebook: www.facebook.com/charmingdisaster Instagram: http://instagram.com/charmingdisasterband YouTube: http://youtube.com/charmingdisasterband Bandcamp: http://charmingdisaster.bandcamp.com Spotify:https://open.spotify.com/artist/1RjkfhamohczSXjFy5WcZh   The Double preorder link: charmingdisaster.bandcamp.com/album/the-double     Tickets : Charming Disaster at The Foundry Cleveland June 5th with Cowboy Princess Brigade https://www.ticketweb.com/event/charming-disaster-cowboy-princess-brigade-the-foundry-tickets/14325923?utm_medium=affiliate&irgwc=1&clickid=yKYzFM2SwxycTOrRPc1Gt0d7UksRjjwhTXGA2E0&camefrom=CFC_BUYAT_219208&impradid=219208&REFERRAL_ID=tmfeedbuyat219208&wt.mc_id=aff_BUYAT_219208&utm_source=219208-Bandsintown&impradname=Bandsintown&ircid=4272   C-Level Pete Francis Tickets : https://www.ticketweb.com/event/peter-francis-of-dispatch-the-winchester-tickets/14338833?utm_source=AllEvents.in&utm_medium=event-discovery-platform&utm_campaign=lakewood-events  

Vaping, initially intended as a smoking cessation tool, has evolved into a harmful trend, especially among young people. Tushi Singh, M.D., and Ricardo Franco, M.D., pulmonologists at Texas Tech Physicians, talk to us about the history of vaping and why it's harmful to our health, and stress seeking professional help for smoking cessation. Dr. Singh's previous episode: "When Breathing Gets Hard: Understanding COPD"Sara Tello, APRN, on smoking cessation: "The Great Escape: Breaking Free from Nicotine Addiction"

VDVV-1755_0932 -Anh Dung Con Bac Sau Lung Hoi Ba Con Hom Nay Co Du Dai Hoi Vui Xuan Khong.mp3PodCast ChannelsVô Vi Podcast - Vấn Đạo  Vô Vi Podcast - Băn GiảngVô Vi Podcast - Nhạc Thiền  

On this episode of JHLT: The Podcast, the Digital Media Editors invite first author Peter Cho and senior author Abbas Ardehali, MD, to discuss the paper, “Severe primary graft dysfunction in heart transplant recipients using donor hearts after circulatory death: a United States Experience.” Peter is a third year medical student at Drexel University, and Dr. Ardehali is professor of surgery and medicine and the Director of the Heart, Lung, and Heart-Lung Transplant programs at UCLA. The episode explores: The study's findings regarding an increased incidence of severe PGD at 24 hours post-transplant in DCD over DBD recipients What risks weren't changed in DCD recipients—suggesting that DCD PGD is likely to be transient, and may have a different phenotype How NRP may impact the outcomes Mitigating the risk of PGD For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Tune in again later this month for the Digital Media Editors' findings and observations from the ISHLT2025 Annual Meeting in Boston. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

John Maytham is joined by Professor Norbert Ndjeka, Chief Director of TB Control and Management at South Africa’s National Department of Health, to spotlight the urgent yet under-recognised crisis of post-TB lung disease. With over 3 million TB survivors in the country and up to 500,000 living with severe lung damage, this condition remains largely invisible in healthcare planning and urgent action is needed to address it. Follow us on:CapeTalk on Facebook: www.facebook.com/CapeTalkCapeTalk on TikTok: www.tiktok.com/@capetalkCapeTalk on Instagram: www.instagram.com/capetalkzaCapeTalk on YouTube: www.youtube.com/@CapeTalk567CapeTalk on X: www.x.com/CapeTalkSee omnystudio.com/listener for privacy information.

Dakala Day (aka Dead Hidden) crept onto the show like a rogue ancestor with a grudge. We dove into ancient wisdom, the secret handshake between lungs and tree roots, and swiped left on the transhumanism agenda. From chasing immortality to arguing with philosophy itself, it got deep, weird, and weirdly enlightening. A must-hear for thinkers, skeptics, and time travelers alike.// FOLLOW DAKALA DAYFOLLOW DEAD HIDDEN☂️☂️☂️☂️☂️☂️☂️☂️☂️☂️☂️☂️☂️☂️☂️☂️☂️☂️☂️ALERT OPERATIONS: CRYPTID WARFARE GET CLEAN: DETOX AND MAKE KIDS HEALTHY AGAIN// // GET 15% OFF AT CHECK OUT USING "PARANOI" at FLAVORS OF THE FOREST⬆️⬆️⬆️// STRUGGLING WITH MENTAL HEALTH? GET $50 OFF  YOUR NEXT LIFE CHANGING TREATMENT AT MENTAL WARIOR by Dr Atwell& VISIT ParanoiRadio.com ☂️

 This week on the SUPERLATIVE Podcast, host and aBlogtoWatch founder Ariel Adams is joined by watch publisher and collector of timepieces, Alfred Lung. Ariel and Alfred Lung dive into the current state of the Hong Kong watch market, exploring the factors that have led to its decline, and the cultural interest in watches among Chinese consumers. They talk about the shifting preferences towards simpler, more practical timepieces, especially with the impact of smartwatches on traditional watch collecting. Throughout their conversation, Ariel and Alfred explore the current state of the watch market, the strategies needed for success in markets like Hong Kong, and the interdependence between big brands and independent watchmakers. As they focus on the resurgence of brands like Parmigiani, they also discuss the vulnerabilities faced by smaller brands, the impact of consumer perception on brand longevity, and the challenges Tudor faces in marketing to a broader audience. The role of watch enthusiasts in providing feedback and quality control for brands is also highlighted, emphasizing the importance of understanding craftsmanship and storytelling in the luxury watch industry. Listen and join in on the conversation with Ariel and Alfred as they fully explore today's watch market in Hong Kong, and so much more, on this week's episode of the Superlative Podcast. Keep up with Alfred:- Alfred on ABTW - https://www.ablogtowatch.com/author/alfred-lung/ - Instagram - https://www.instagram.com/alfred.is.watching/ SUPERLATIVE IS NOW ON YOUTUBE! To check out Superlative on Youtube as well as other ABTW content:- YouTube - https://www.youtube.com/@ablogtowatch To check out the ABTW Shop where you can see our products inspired by our love of Horology:- Shop ABTW - https://store.ablogtowatch.com/To keep updated with everything Superlative and aBlogtoWatch, check us out on:- Instagram - https://www.instagram.com/ablogtowatch/- Twitter - https://twitter.com/ABLOGTOWATCH- Website - https://www.ablogtowatch.com/If you enjoy the show please Subscribe, Rate, and Review!

Show Notes: We're joined by Ron Chapman — lung transplant recipient, author, and passionate advocate for those awaiting a second chance at life. In a powerful conversation, Ron shares his deeply personal story of resilience, fear, hope, and gratitude. Through his heartfelt discussion with our hosts and his inspiring book, A Quest for a Lung, Ron offers guidance and encouragement to anyone on the transplant journey. In this episode's Mental Health Moment, we explore the power of resilience and share practical tips for overcoming life's toughest challenges. Finally, we pay tribute to donor hero Asher Chavers.

Program notes:0:47 Gun injuries and deer hunting season1:47 Other associated injuries2:47 Coincidence of hunting?3:48 Restrict hunting guns to that use4:10 Can we avoid surgery in some with cancer?5:10 Dostarlimab treatment6:10 Can help avoid surgery in few who have this mutation7:10 Look at specific pathways7:30 Lung cancer treatment8:32 71% responded9:12 Impact of Pepfar funding freeze10:12 Looked at waiver scenarios11:12 Decreased deaths and infection12:13 Takes time to resume13:06 End

In this week's episode, we'll hear about how researchers look toward the lung, and find uniquely programmed blood stem cells. This study is the first to fully characterize hematopoietic stem and progenitor cells in the adult human lung. After that: researchers develop a neural network-based probabilistic classifier, DLBclass, that assigns all diffuse large B-cell lymphomas into one of five genetic subtypes. It's an inclusive taxonomy that they say provides actionable genetic information in almost all patients with DLBCL. Finally, new insights on NETS, or neutrophil extracellular traps. In the liver vasculature, NET removal leads to secondary inflammation, resulting in new waves of NETS that may impact future infection. We'll review these and other findings from this recent mouse model study.Featured Articles:Decoding functional hematopoietic progenitor cells in the adult human lungDLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphomaDonor regulatory T-cell therapy to prevent graft-versus-host disease

A study of almost 250.000 people found people who vape had a far higher risk of getting Chronic Obstructive Pulmonary Disease, a serious, incurable disease that makes breathing difficult. Asthma and Respiratory Foundation NZ Chief Executive Letitia Harding spoke to Ingrid Hipkiss.

In this episode, Katie discusses the importance of lung health, particularly in the context of springtime and rising pollen levels. She explores the role of the lungs in both Western and Chinese medicine, emphasizing their connection to emotional health and overall well-being. The episode provides practical tips for maintaining lung health, including breathing techniques, mindfulness practices, and environmental considerations. More information here: https://katiebrindle.com/ Subscribe to my newsletter: https://katiebrindle.com/newsletter-s... Buy 'Yang Sheng: The Art of Chinese Self-Healing' at https://www.hayoumethod.com/product/y... Buy the Hayo'u tools at https://www.hayoumethod.com/products/ Hayo'uFit at https://hayoufit.com -------------------------------------------- Join my channel and leave a comment about what you want to see next! Love, Katie Brindle. Learn more about your ad choices. Visit podcastchoices.com/adchoices Learn more about your ad choices. Visit podcastchoices.com/adchoices

Elijah Lung is a multifamily real estate investor and capital raiser with over 30 years of experience in the industry. Starting his career as a farmhand, Elijah built a multi-seven-figure business in cattle waste management before transitioning into farmland investments and, ultimately, multifamily syndication. His unconventional journey—from managing messy assets to raising millions for large-scale real estate deals—makes him a uniquely insightful guest for anyone interested in building wealth through real estate. On this episode we talk about: Elijah's journey from farmhand to successful business owner and real estate investor How he built and exited a cattle waste management business Transitioning from farmland investing to multifamily real estate syndication The challenges and realities of raising $1 million for a $39 million multifamily deal Building trust and credibility with investors in the capital raising process Top 3 Takeaways Trust and relationships are everything in capital raising—credibility is built over time, not overnight Success in multifamily investing often comes from persistence, education, and leveraging your network The realities of raising capital are far more challenging than they appear; cold calls, follow-ups, and handling rejection are all part of the process Connect with Elijah: https://www.linkedin.com/in/elijahiung Learn more about your ad choices. Visit megaphone.fm/adchoices

Host: Darryl S. Chutka, M.D. Guest: John Haney, M.D., M.P.H. Lung transplantation remains a very viable option for patients with end-stage pulmonary disease who no longer respond to medical management. Over 5,000 lung transplants are performed annually around the world. However, its estimated that over 10 times this number are candidates and awaiting a transplant. A shortage of organs remains the major limiting factor. What are the common indications and who's a candidate for a lung transplant? How are patients prioritized and chosen? What advances have been made in the field and what challenges remain? Finally, what role does the primary care clinician play in lung transplantation? I'll be discussing these questions and more with my guest, Jack Haney, M.D., M.P.H., chair of cardiothoracic surgery at the Jacksonville campus of the Mayo Clinic. The topic for this podcast is “Lung Transplantation”. Learn more about this Transplant Series:  Mayo Clinic Talks: Donate Life: Transplantation Series | Mayo Clinic School of Continuous Professional Development Connect with Mayo Clinic's Transplant Center online at https://mayoclinic.org/transplant or on X @MayoTransplant. To learn more and register to be an organ donor please visit https://careinfo.mayoclinic.org/organ-donation. Connect and listen with Mayo Clinic Podcasts | Mayo Clinic School of Continuous Professional Development

Live from Texas Lung - Patient Education by IASLC

Tuesday, April 22 -  Host Doug Stephan and Dr. Ken Kronhaus of Lake Cardiology (352-735-1400) cover a number of topics affecting our health. First up, Doug and Dr. Ken start with one new study finding that pedestrians have an increased risk of being hit by an electric or hybrid-electric vehicle, another study predicting global life-expectancy to rise, and the current state of covid, RSV, the flu, and the avian flu. Then, Doug and Dr. Ken discuss the peculiar link between 7+ hours of social media a day and how it contributes to an increased likelihood of smoking, and new research suggests cannabis use can raise a users odds for a psychotic episode with a stronger link than previously thought. Then, a discussion on why some people notice their allergies getting worse year after year and how age affects allergy symptoms as well as location, new hope to extend the life of patients with advanced forms of deadly lung cancers, and the latest on popular weight loss drugs. Then, Doug Stephan is joined by Elizabeth Miller to discuss the favorite weight loss capsules, Calotren, and why taking the capsules before you go to bed can have a positive impact on sleep. It's not just for healthy and sustainable weight loss. The best part, listeners of Doug Stephan's Good Day Networks radio programs and podcasts are privy to a special deal: use the code “DOUG” at checkout for extra savings.Website: GoodDayHealthShow.com Social Media: @GoodDayNetworks

Send us a textLung Recruitment Before Surfactant Administration in Extremely Preterm Neonates: 2-Year Follow-Up of a Randomized Clinical Trial.Gallini F, De Rose DU, Iuliano R, Romeo DM, Tana M, Paladini A, Fusco FP, Nobile S, Cota F, Tirone C, Aurilia C, Lio A, Esposito A, Costa S, D'Andrea V, Ventura ML, Carnielli V, Dani C, Mosca F, Fumagalli M, Scarpelli G, Giordano L, Fasolato V, Petrillo F, Betta P, Solinas A, Gitto E, Gargano G, Mescoli G, Martinelli S, Di Fabio S, Bernardo I, Tina LG, Staffler A, Stasi I, Mondello I, Scapillati E, Vedovato S, Maffei G, Bove A, Vitaliti M, Terrin G, Lago P, Gizzi C, Strozzi C, Villani PE, Berardi A, Cacace C, Bracaglia G, Pascucci E, Cools F, Pillow JJ, Polglase G, Pastorino R, van Kaam AH, Mercuri E, Orfeo L, Vento G; IN-REC-SUR-E Study Group; Malguzzi S, Rigotti C, Cecchi A, Nigro G, Costabile CD, Roma E, Sindico P, Venafra R, Mattia C, Conversano M, Ballardini E, Manganaro A, Balestri E, Gallo C, Catenazzi P, Astori MG, Maranella E, Grassia C, Maiolo K, Castellano D, Massenzi L, Chiodin E, Gallina MR, Consigli C, Sorrentino E, Bonato S, Mancini M, Perniola R, Giannuzzo S, Tranchina E, Cardilli V, Dito L, Regoli D, Tormena F, Battajon N, Arena R, Allais B, Guidotti I, Roversi F, Meli V, Tulino V, Casati A.JAMA Netw Open. 2024 Sep 3;7(9):e2435347. doi: 10.1001/jamanetworkopen.2024.35347.PMID: 39320892 Free PMC article. Clinical Trial.As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

A lawsuit against a former Indianapolis Public Schools teacher, alleging systemic abuse against a student, has been dismissed. A large-scale cleanup of an east side waterway and greenspace is planned for this Earth Day weekend. Residents who live in rural areas or lack transportation may struggle to access lung screenings. Forty percent of the staff in the U.S. Education Department Office for Civil Rights have been laid off under President Trump's administration, and parents say their complaints of discrimination in schools are not being investigated. Want to go deeper on the stories you hear on WFYI News Now? Visit wfyi.org/news and follow us on social media to get comprehensive analysis and local news daily. Subscribe to WFYI News Now wherever you get your podcasts. WFYI News Now is produced by Drew Daudelin, Zach Bundy and Abriana Herron, with support from News Director Sarah Neal-Estes.

Leave a Review/Comment or Ask a Question. Scroll down past the 'Ratings and Review' section and look for the 'Write a Review' link..... if you get to the 'About' section you've gone too far. Seems to work best on a mobile device rather than a laptop. If you don't have an Apple device leave your comment or review on our Youtube page..... Thank you so much. :)Youtube Channel - You'll find all of our videos here. Leave comments, suggestions or questions in the comments section of a video. (Subscribe if you fancy it.... could be fun.)Leave A Tip - We appreciate your support.... and it means we can buy Buddy a new blanket as he tends to chew holes in them. ------------------------We get asked questions every day by our clients both in person at our clinic, and also through our online platforms. All questions tend to fall under one of the Five Main Health Pillars;NutritionSleepMindsetExercise/MovementBreath WorkWe answer these question based upon over 17 years of clinical experience, and what we learn from the vast array of collaborators we work alongside and learn from every day. We don't see people in the same field as competitors, we see them as potential collaborators. It's much more rewarding, interesting, and infinitely much more fun when you approach your life seeing the abundance of opportunities out there, rather than desperately trying to cling to your own small bit of territory and see those around you as a threat. Nobody can replicate what you do, because there is nobody else like you in the world....... and there never will be again. So, you could use an idea from somebody else, but put your own personality into it. Then it becomes your own. We love hearing from our listeners and clients to hear where they need help, and it's so interesting to hear how we have helped start the ball rolling, but they are the ones that have ultimately found the formula that works best for them...... we're there to help bounce ideas, provide experience and encourage you to experiment and enjoy the journey on the way to the goals they've set themselves. I'm rambling I know.... but that's because this isn't a pre-meditated calculated marketing script. This is me sat of my sofa with our dog Buddy (he's helping me obviously!) tapping this out on my laptop in stream of consciousness. Life is fun, people are wonderful, and we are so fortunate to be in a position to help those who choose to visit our clinic and seek our guidance through our online platforms.Useful LinksElevate Health Chiropractic and Wellbeing Website - Our clinic website. Elevate Health Online Membership Registration - If you'd like to work with us online click on this link and we'll look forward to starting the process.

Dre Harrison is back to host another episode of Tank Slappers after a newsworthy Grand Prix of Qatar, joined by Autosport and Motorsport.com writers Uri Puigdemont and Richard Asher.  Once again it was Marc Marquez who dominated from the front to take his third double victory of the season in the Sprint and the Grand Prix. The trio talk about Marquez's brilliance despite the early clash with his brother Alex, and the worry for teammate Francesco Bagnaia, who was expected to win on a track he's won at multiple times before. There's also the latest news on the condition of World Champion Jorge Martin, who suffered a horrendous crash after being struck by Fabio DiGiannantonio, and is set to miss three months of racing after having his lung collapse and breaking 11 of his ribs.  Maverick Vinales shocked everyone in the sport by giving Marquez a run for his money by finishing second on the road, only to drop to 14th after the race finished due to a breach of the tyre pressure regulations. Dre and Richard discuss whether the rule needs changing after Vinales spent multiple laps leading to bring his tyre pressures down.  There's also the polarising performances coming from the Japanese manufactures, as Honda's Johann Zarco continues to impress with a fourth-placed finish, while Fabio Quartararo falls down the order after claiming his first front-row start in nearly three years. 

Stupid News 4-10-2025 8am ...A Luxury Hotel in Scotland Really F**ked Up ...Hey, why does this Duck taste like Pigeon? ...Wait, what? How did he give himself a Fungal Lung Infection?

Averted lung cancer deaths due to reductions in cigarette smoking in the United States, 1970–2022  Cancer Smoking prevalence peaked in the 50s and 60s but has declined following the US Surgeon General's report in 1964 on its health risk. As 85% of lung cancer is attributable to smoking, the authors evaluated this impact by assessing lung cancer deaths averted, and person-years of life (PYL) gained between 1970 and 2022 using cancer mortality data from the CDC. The authors estimated 3,856,240 lung cancer deaths were averted and 76,275,550 PYL were gained during the study period (average of 19.8 PYL gained per death averted). The deaths averted were higher in men (2,246,610), but average PYL gained per death averted was higher in women (22.4 years). Lung cancer deaths averted accounted for 51.4% of the estimated decrease in overall cancer deaths.  The findings highlight the importance of tobacco controls and interventions and need for ongoing efforts to decrease tobacco use.    Read this issue of the ASAM Weekly Subscribe to the ASAM Weekly Visit ASAM

Full article: Prognostic Implications of the Volume Doubling Time of the Solid Component in Lung Adenocarcinomas Manifesting as Part-Solid Lesions on Chest CT Aisha Alam, DO, discusses the AJR article by Ahn et al. exploring the importance of the volume doubling time of the solid component in lung cancers appearing as part-solid nodules.

Watches and Wonders 2025!

Katie kicks off the show with Dr. Jess and talks about different diet options for dogs with lung health issues Learn more about your ad choices. Visit podcastchoices.com/adchoices

Katie kicks off the show with Dr. Jess and talks about different diet options for dogs with lung health issues Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Today, I am delighted to connect with my physician colleague, Dr. Vivek Lal. He is a physician-scientist, a double board-certified physician, an innovator, and an entrepreneur. He is also the Director of Clinical Innovation at the Marnix Heersink Institute of Biomedical Innovation and Professor and Director of the Pulmonary Microbiome Lab at the University of Alabama at Birmingham. In today's conversation, we dive into the lung microbiome, examining the anatomy and physiology of the lungs, gas exchange, and why air is medicine. We discuss the realities of lung function, looking at the lung microbiome, dysbiosis, the concept of leaky lung, and the gut-lung relationship, and explore how lifestyle, exercise, and nutrition impact lung health and how sleep deprivation and stress can lead to lung infections and inflammation. We also get into specific diagnoses related to lung health, the effects of environmental toxins, and the latest cutting-edge research on probiotics that may benefit lung health, and touch on the consequences of long-term steroid use for chronic conditions and how menopause impacts the lung microbiome. I know you will love this invaluable conversation with Dr. Vivek Lal. IN THIS EPISODE YOU WILL LEARN: Dr. Lal explains the anatomy and physiology of the lungs Why Dr. Lal believes air is medicine How the lung microbiome compares with the gut microbiome  How the concept of real lung function can prevent secondary health issues  How lifestyle factors influence lung health How the gut-lung axis affects lung health How ResB Lung Support, the world's first respiratory probiotic, was developed  The benefits of using the ResB Lung Support probiotic  How probiotics can reduce the side effects of long-term steroid use Bio: Dr. Vivek Lal Dr. C. Vivek Lal, MD, is a physician-scientist, innovator, and entrepreneur. He is the Director of Clinical Innovation at the Marnix Heersink Institute of Biomedical Innovation, Professor, and the Director of the Pulmonary Microbiome Lab at the University of Alabama at Birmingham (UAB). Dr. Lal is the founder of Alveolus Bio, Inc., a biotech platform company that does FDA-approved pulmonary drug development. He is also the founder and CEO of ResBiotic Nutrition, Inc., a company that makes science-backed wellness supplements, and Urgent Care for Children, a Southeast US-based urgent care chain headquartered in AL. Connect with Cynthia Thurlow          Follow on Twitter Instagram LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Connect with Dr. Vivek Lal On the ResBiotic website Email Dr. Lal: Vikek@resbiotic.com 

Holmberg's Morning Sickness - Brady Report - Monday February 24, 2025 Learn more about your ad choices. Visit podcastchoices.com/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Holmberg's Morning Sickness - Brady Report - Monday February 24, 2025 Learn more about your ad choices. Visit podcastchoices.com/adchoices